ALBO News and Press, Albireo Pharma Inc. From 05/17/22

Albireo Pharma (NASDAQ:ALBO -19.9%) stock plunged on Tuesday after the company posted lower-than-expected quarterly revenue and wider-than-expected loss, hurt by fall in demand for skin treatment, Bylvay. Quarterly revenue rose 248.5% Y/Y to $6.83M, but missed analysts estimate by $...

Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma  (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...

Albireo Pharma, Inc. (ALBO) Q1 2022 Earnings Conference Call May 16, 2022 16:30 ET Company Participants Hans Vitzthum - Managing Director-LifeSci Advisors, LLC Ron Cooper - President & Chief Executive Officer Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Off...

Albireo Pharma press release (NASDAQ:ALBO): Q1 GAAP EPS of -$2.19 misses by $0.39. Revenue of $6.83M (+248.5% Y/Y) misses by $0.42M. For further details see: Albireo Pharma GAAP EPS of -$2.19 misses by $0.39, revenue of $6.83M misses by $0.42M

Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled, patient numbers above original target and on track for topline data ...

ADMP, ALBO, ANY, AREC, ASTS, AXDX, CCSI, OTCQX:CWBHF, CWBR, CYRN, DAC, DADA, DNA, EGLX, FTK, FUV, GAN, GLBE, GNLN, HYRE, INPX, IONQ, IPWR, ISUN, IZEA, KBNT, KULR, MARK, MVST, OTCQB:NEXCF, NU, OTCQX:PLNHF, PPSI, PYR, QIPT, REED, REKR, RGTI, RKLB, RMTI, SHLS, OTCQX:SHWZ, SLGG, SNDL, SPI, SPRO, ...

Albireo Pharma (NASDAQ:ALBO) Q1 consensus EPS estimate is -$1.71 and consensus revenue estimate is $7.25M. ALBO is scheduled to announce Q1 earnings results on Friday, May 13, after market close. For further details see: Albireo Pharma Q1 2022 Earnings Preview

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on May 16, 2022, to provide a busine...

The lead medicine (Bylvay) is already approved to treat an orphan disease known as progressive familial intrahepatic cholestasis. Leveraging a prudent growth strategy, Albireo is aggressively expanding Bylvay's label for other rare conditions. Due to the biotech bear market, the s...

Albireo Pharma Inc. (NASDAQ:ALBO) traded at a new 52-week high today of $52.81. So far today approximately 9.3 million shares have been exchanged, as compared to an average 30-day volume of 327,000 shares. Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on ...